Uterine Cancer
125
23
27
60
Key Insights
Highlights
Success Rate
82% trial completion
Published Results
23 trials with published results (18%)
Research Maturity
60 completed trials (48% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
10.4%
13 terminated out of 125 trials
82.2%
-4.4% vs benchmark
5%
6 trials in Phase 3/4
38%
23 of 60 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 60 completed trials
Clinical Trials (125)
Tissue Acquisition and Genomics Analysis of Breast Cancer and Other Gynecologic Malignancies
AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma
Liquid Biopsy Evaluation and Repository Development at Princess Margaret
Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients
PROton Therapy for Post Surgical Treatment of GYNecologic Cancer
Ovarian-Sparing Adaptive Radiotherapy in Young Adult Women
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Investigations of Reproductive Cancers in Women
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Initial Testing of a Behavioral Intervention About Genetic Services for Families at Risk of Lynch Syndrome
COQ10 and Vitamin E for Off-Target Radiation Toxicity
Study of NEO-201 in Solid Tumors Expansion Cohorts
A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)
[18F]FES PET/.CT in Uterine Cancer
Performance of SYMMCORA® vs. V-Loc® Suture Material in Patients Undergoing Laparoscopic Total Hysterectomy
Physical Activity Intervention Among Older Women With Gynecologic Cancers (Fit4Treatment)
Measurement of Urinary Hormones in Patients With Abnormal Uterine Bleeding to Study Uterine Cancer Progression
A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies
Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma
Cancer Loyalty Card Study 2 (CLOCS-2)